NewAmsterdam Pharma Company N.V. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
NewAmsterdam Pharma Company N.V. (NAMS) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$63.98 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-05
- NewAmsterdam Pharma Company N.V. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$31.05M.
- NewAmsterdam Pharma Company N.V. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$27.09M, a 118.92% decline year-over-year.
- NewAmsterdam Pharma Company N.V. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was $143.19M.
- NewAmsterdam Pharma Company N.V. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$29.48M.
- NewAmsterdam Pharma Company N.V. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$293.18M, a 166.92% decline from fiscal 2024.
- NewAmsterdam Pharma Company N.V. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $438.10M.
- NewAmsterdam Pharma Company N.V. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$132.33M, a 132.89% decline from fiscal 2022.
- NewAmsterdam Pharma Company N.V. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was $402.35M, a 629.32% increase from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$63.98M 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | -$31.05M 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | -$293.18M 10-K · filed 2026-02-18 | |||
| 2025-09-30 | -$244.85M 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | -$220.48M 10-Q · filed 2026-08-05 | |||
| 2025-03-31 | -$27.09M 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | $438.10M 10-K · filed 2026-02-18 | |||
| 2024-09-30 | $81.14M 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | $93.66M 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | $143.19M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | -$132.33M 10-K · filed 2026-02-18 | |||
| 2023-09-30 | -$99.25M 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | -$52.45M 10-Q · filed 2024-08-07 | |||
| 2023-03-31 | -$29.48M 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $402.35M 10-K · filed 2025-02-26 | |||
| 2021-12-31 | $55.17M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |